Skip to content

To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment

A Prospective, Randomized Controlled Study to Investigate the CLBRs of GnRH Antagonist Protocol Compared With the Standard GnRH Agonist Long Protocol for Controlled Ovarian Stimulation in Supposed Normal Ovarian Responders

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04026282
Acronym
CLBR
Enrollment
888
Registered
2019-07-19
Start date
2018-12-27
Completion date
2022-07-31
Last updated
2019-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sterility

Keywords

assisted reproductive technology, live birth, fertilization

Brief summary

This is a Phase IV, prospective, randomized controlled study to investigate the cumulative live birth rates (CLBRs) of gonadotrophin-releasing hormone (GnRH) antagonist protocol (GnRH-ant group) compared with the standard GnRH agonist long protocol (GnRH-a group) for controlled ovarian stimulation in supposed normal ovarian responders.

Detailed description

This is a Phase IV, prospective, randomized controlled study to investigate the cumulative live birth rates (CLBRs) of gonadotrophin-releasing hormone (GnRH) antagonist protocol (GnRH-ant group) compared with the standard GnRH agonist long protocol (GnRH-a group) for controlled ovarian stimulation in supposed normal ovarian responders. In this study, patients who are planning to undergo IVF/ICSI cycle aged ≤38 years old with normal ovarian reserve will be considered for enrollment. Approximately 888 patients will be enrolled at approximately 5 centers in China over a period of 10 months. About 12-20 visits will be performed in this study for each patient. The CLBR with first live birth resulting from one initiated COS cycle will be compared between GnRH-a group and GnRH-ant group.

Interventions

PROCEDUREGnRH-ant protocol

Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.

PROCEDUREGnRH-a long protocol

The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.

Sponsors

Merck Serono GmbH, Germany
CollaboratorINDUSTRY
Fountain Medical Development Co., Ltd.
CollaboratorINDUSTRY
Guangzhou KingMed Center for Clinical Lab.Co., Ltd
CollaboratorUNKNOWN
Peking University Third Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

When patients enter this study, they will be randomly assigned to GnRH-ant group or GnRH-a group at ratio1:1 by the randomization schedule generated by a computer program.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* Infertile women planning to undergo IVF/ICSI cycle using conventional GnRH agonist long protocol or GnRH antagonist protocol * Age ≤ 38 years old * Basal AFC 8\ 20 * Basal FSH≤10 IU/L * Basal E 2 \<200pmol/L * Normal uterus and at least one side of the normal ovary * Informed consent form signed * Willing to follow the study protocol, and able to complete this study

Exclusion criteria

* Previous IVF/ICSI cycles \>2 * Severe hydro-salpinx (Ultrasound shows hydro salpinx﹥2cm) * Severe endometriosis (Grade III - IV) * Polycystic ovarian syndrome (PCOS) * History of recurrent miscarriages (\>2 times of miscarriages) * Plan to undergo ovarian stimulation for preimplantation genetic diagnosis or preimplantation genetic screening, oocyte donation, and social or medical freezing of oocytes * Any major systemic disease that as per Investigator's discretion precludes subject for participation in the study * With pregnancy contraindications * Alcoholism, drug abuse, drug addiction or patients with uncured sexually transmitted disease * According to the judgment of the Investigator, any medical condition or any concomitant surgery/medications that would interfere with evaluation of study medications * Simultaneous participation in another clinical study * Plan to use urinary gonadotrophin during COS treatment

Design outcomes

Primary

MeasureTime frameDescription
the cumulative live birth ratestwo yearsTo investigate the cumulative live birth rates in infertile women ≤ 38 years old with normal ovarian from one initiated COS cycle. reserve using GnRH antagonist or agonist protocol for COS in ART treatment Numerator is the No. of women got their first live birth, the Denominator is the No. of women who attempt the ovarian stimulation. There will be two ways to calculate the CLBR: * The conservative estimate of the cumulative live birth rate, which is based on the assumption that none of the women who do not return for a subsequent embryo transfer would have had a live birth. * The optimal estimate of the cumulative live birth rate, which is based on the assumption that women who do not return for a subsequent embryo transfer would have had the same live birth rates as those who do return.

Secondary

MeasureTime frameDescription
Good-quality embryo rate (The Istanbul Consensus29)24 hours after Oocytes pick upTotal the number of good quality embryos divided by Total the number of embryos
hCG positive rateafter 11 to 17 days of ETNumerator is the No.of β-hCG blood test which is positive results, he Denominator is the No. of β-hCG blood test. HCG test is Serum β-hCG test after 11 to 17
Implantation rate4 to 6 weeks after ETthe number of gestational sacs observed divided by the number of embryos transferred
Clinical pregnancy rateafter 4 to 6 weeks of ETthe number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, or embryo transfer cycles. Note: When clinical pregnancy rates are given, the denominator (initiated, aspirated, or embryo transfer cycles) must be specified.
Ongoing pregnancy rateafter 12 weeks of ETthe number of . Ongoing pregnancy divided by the number of Clinical pregnancy . Ongoing pregnancy is intrauterine pregnancy continued for 12 gestational weeks (detection of presence of gestational sac with fetal heartbeat by transvaginal ultrasound examination in week 12).
Live birth ratetwo yearsNumerator is the No. of women got live birth resulting from fresh cycle (multiple births considered as one live birth), the Denominator is the No. of women who attempt the ovarian stimulation.
Cumulative clinical pregnancy ratetwo yearsNumerator is the No. of women got their first clinical pregnancy, the Denominator is the No. of women who attempt the ovarian stimulation.
Number of oocytes retrieved24 hours after Oocytes pick uprecorded Number of oocytes retrieved on DOPU
Ectopic pregnancy rateafter 4 to 6 weeks of ETthe number of .extrauterine pregnancy divided by the number of Clinical pregnancy .
Cycle cancelled rate and reasonOn ART cycleCancelled cycle is an ART cycle in which ovarian stimulation or monitoring has been carried out with the intention to treat, but which did not proceed to follicular aspiration or, in the case of a thawed embryo, to embryo transfer. Cycle cancelled rate is the number of Cancelled cycle divided by the number of embryos transferred.
severity of OHSStwo weeks after Oocytes pick upAssessed the severity of OHSS.
Rate of OHSStwo weeks after Oocytes pick upthe number of OHSS divided by the number of ovum pick up. Assessed the severity of OHSS.
Time to pregnancy4 to 6 weeks after ETtime from Gn Initiation to the first clinical pregnancy.
Time to live birthnine months after pregnancytime from Gn Initiation to the first live birth
the SafetyTwo years after signature of informed consentData on AEs will be collected at scheduled and unscheduled visits, based on information spontaneously provided by the subject and/or through questioning of the subject.
Miscarriage rateafter 12 weeks of ETthe number of Miscarriage which is the natural death of an embryo or fetus before it is able to survive independently divided by the number of Clinical pregnancy .

Countries

China

Contacts

Primary ContactQiao Jie
jie.qiao@263.net010-82265080
Backup ContactRui Yang
yrjeff@126.com13810002416

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026